Abstract
Rituximab, a chimeric monoclonal antibody against B cell-specific surface marker CD20, has shown encouraging results in treating autoimmune diseases.1–4 In this study, six patients with refractory severe thrombocytopenia (platelets (PLT)...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
